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DOI 10.1186/s12962-015-0029-9RESEARCH Open AccessRevisiting the cost-effectiveness of universal
HPV-vaccination in Denmark accounting for all
potentially vaccine preventable HPV-related
diseases in males and females
Jens Olsen1,2* and Tine Rikke Jørgensen3,4Abstract
Objective: The purpose of this study was to assess the consequences of a national immunization program with
HPV vaccine for both boys and girls in Denmark, including the prophylactic effects on all potentially vaccine
preventable HPV-associated diseases in male and female.
Methods: The study focussed on the quadrivalent vaccine which protects against HPV type 6, 11, 16 and 18, and
the vaccine’s protection against genital warts, cervical intraepithelial neoplasia, cervical cancer, anogenital cancer
(anal, penile, vaginal and vulvar cancer) and head and neck cancer (oral cavity, oropharyngeal, hypopharyngeal and
laryngeal cancer) were included in the analyses. In general, the analysis was performed in two phases. First, an
agent-based transmission model that described the HPV transmission without and with HPV vaccination was
applied. Second, an analysis of the incremental costs and effects was performed. The model did not include
naturally-acquired immunity to HPV in the simulations.
Results: In the base case result (i.e. vaccination of girls only, 85% vaccination rate, private market price at € 123
per dose ex. VAT) an ICER of 3583 €/QALY (3-dose regime) is estimated when all HPV-related diseases are taken
into account. Vaccination of girls & boys vs. vaccination of girls only an ICER of 28,031 €/QALY (2-dose regime)
and 41,636 €/QALY (3-dose regime) is estimated.
Conclusions: Extension of the current HPV programme in Denmark to include boys and girls is a cost effective
preventive intervention that would lead to a faster prevention of cancers, cancer precursors and genital warts in
men and women.
Keywords: HPV-vaccination, Cost-effectiveness, HPV-related diseases, Cancer, Genital warts, Gender neutral vaccinationIntroduction
Persistent human papillomavirus (HPV) infections with
HPV genotype 16 and genotype 18 are responsible for
about 70% of all cervical cancer [1-3]. HPV causes not
only cervical cancer, but is also accounting for 40-85% of
cases of anal, penile, vaginal, and vulvar cancer. Not only
anogenital cancer is linked to HPV, but also some head
and neck cancers, as 16-28% of cancers of oral cavity,* Correspondence: jo@incentive.dk
1Centre for Applied Health Services Research and Technology Assessment
(CAST), University of Southern Denmark, 5000 Odense C, Denmark
2Incentive, 2840 Holte, Denmark
Full list of author information is available at the end of the article
© 2015 Olsen and Jørgensen; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.oropharyngeal, hypopharyngeal, and laryngeal are attrib-
utable to HPV [4]. HPV 16 and HPV 18 cause most of
the HPV linked anogenital cancer and head and neck
cancers, as HPV 16 or 18 are accounting for 74-100% of
all these cancers [5-11]. HPV is a cause of not only can-
cer, the HPV types HPV 6 and 11 cause about 90% of
anogenital warts [12]. In addition juvenile onset of re-
current respiratory papillomatosis is also caused by HPV
types 6 and 11 [13].
Two vaccines are currently available on the market: a
quadrivalent (including HPV genotypes 16, 18, 6 and 11)
and a bivalent vaccine (including genotypes 16 and 18).
Both vaccines effectively protect against precancerousCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in addition, the quadrivalent prevents precancerous anal
lesions, anal cancer and anogenital warts.
Currently, HPV vaccination of adolescent girls is part
of the national immunization programme in a number
of countries [14-16]. In the past 5-6 years, numerous
cost-effectiveness studies of HPV-vaccination evaluating
various vaccination scenarios have been published
[14,16-23]. However, few studies include the prophylac-
tic effect of all HPV-associated diseases [18,19,22], des-
pite the considerable burden of non-cervical HPV
disease – especially in men [18,24,25]. This applies e.g.
in Denmark, where the burden of HPV-linked cancer, in
particular HPV 16 linked head and neck cancer, is higher
in men than in women [25]. In recent years, there has
been a moderate decrease in the cervical cancer inci-
dence in Denmark whereas the incidence in head and
neck cancer has been increasing. In 2012, the incidence
rate (i.e. age adjusted incidence per 100,000) for cervical
cancer was 12.7, the incidence rate for anogenital cancer
(i.e. anal, penile (in men), vaginal (in women), and vulvar
(in women) cancer) was 6.4 in women and 3.6 in men
and the incidence rate for head and neck cancer (i.e.
cancers of oral cavity, oropharyngeal, hypopharyngeal,
and laryngeal) was 8.9 in women and 19.6 in men [26].
Since 2009, the national immunization programme in
Denmark offers free quadrivalent human papillomavirus
vaccine to all girls aged 12 years. Furthermore, in 2012
and 2013 a catch up program was implemented for all
women up to 27 years old.
The purpose of this study was to assess by modelling
the economic consequences of a national immunization
program with publicly financed quadrivalent HPV vac-
cine for both boys and girls aged 12 years or a for only
girls aged 12 years in Denmark compared with screening
program alone, including the prophylactic effects on all
HPV-associated diseases.
Methods
The following scenarios were analysed in the study:
 the cost-effectiveness of vaccinating 12-year-old girls
in Denmark compared to no HPV vaccination
and
 the cost-effectiveness of vaccinating 12-year-old girls
and boys in Denmark compared to vaccinating girls
alone.
The study focussed on the quadrivalent vaccine which
protects against HPV type 6, 11, 16 and 18, and the vac-
cine’s protection against genital warts, cervical intrae-
pithelial neoplasia, cervical cancer, anogenital cancer(anal, penile, vaginal and vulvar cancer) and head and
neck cancer (oral cavity, oropharyngeal, hypopharyngeal
and laryngeal cancer) were included in the analyses.
Protection against recurrent respiratory papillomatosis
was not included in the analysis among others because
no Danish study reports the costs of recurrent respira-
tory papillomatosis.Model simulations and assumptions
A previously developed and published model was used
[15,27]. This model has also been applied in an Irish set-
ting by the national authorities [28].
The analysis was performed in two phases. First,
using the software NetLogo (version 4.0.2) (http://ccl.
northwestern.edu/netlogo), an agent based transmis-
sion model was developed that describes the HPV
transmission dynamics before and after introduction of
HPV vaccination. Second, an analysis of the incremental
costs and effects was performed using Microsoft® Excel.
A more comprehensive description can be found in
[15] and the original Health Technology Assessment
[27] includes an exhaustive description (20 pages) of
the model.
In the agent based model the transmission and
possible clearance of HPV 6, 11, 16 and 18 was simu-
lated in a heterosexual population and for persistent
HPV infections, the subsequent development of genital
warts, cervical intraepithelial neoplasia (CIN1–3) and
cervical cancer were also simulated. No natural immun-
ity following infection was assumed, suggesting that an
individual infected by one type of HPV has the same risk
of being re-infected by the same type.
The acquisition of HPV infection and natural course
of HPV related cancers at non-cervical sites are poorly
understood. Hence, it is difficult to construct a model of
HPV infection and disease in these sites that accurately
captures the underlying biological processes [29]. As a
simplification, it was assumed that the incidence of HPV
attributable to non-cervical cancers will decrease at the
same rate (proportionately) as cervical cancer, as pre-
dicted by the transmission model.
The model operates with several variables, some of
which relate to the entire population (e.g. CIN progres-
sion and regression probabilities, risk of HPV infection
per sexual act) and some of which are agent-specific (e.g.
age, sex, duration of relationship), see Table 1.
It was assumed that the current Danish cervical
screening program remained unchanged implying that
women aged 23-64 years are offered screening every 3-5
years. Therefore, cervical cancer screening was not mod-
elled. A 62-year time horizon was applied implying that
the first year group of 12-year-olds are followed until the
age of 74 years in order to include all costs and benefits
Table 1 Parameters applied in the HPV transmission model
Variable Value Source
Age groups included 10-78 years, present Danish age distribution Age distribution: Statistics Denmark
Gender Man/woman Fixed at 50%
Concurrent partners 0, 1 or 2, uniform/block distribution Estimate.
Duration of relationship (in months) Based on estimate, dependent of age, that is the older the longer
duration (Y = abs random-normal (0.8·age – 12) (age/0.5)·12).
Estimate
Frequency of sexual intercourse Random-gamma distribution with a mean of 9.48 per month;
SD 9.95
Burchell et al. [30]
Vaccination status 0 or 1
HPV-specific:
Duration of HPV 6 infection (in months) Exponential distribution with a mean of 11 months The estimate is set in order to calibrate the
model before introduction of a vaccine
Duration of HPV 11 infection (in months) Exponential distribution with a mean of 9.5 months
Duration of HPV 16 infection (in months) Exponential distribution with a mean of 13 months
Duration of HPV 18 infection (in months) Exponential distribution with a mean of 11 months
HPV→ CIN1 0.0049 per month (probability)
CIN1→ HPV/clear (regress) 0.329 per year (probability) Elbasha et al. [17]
CIN1→ CIN2 0.46 per year (probability) The estimate is set in order to calibrate the
model before introduction of a vaccine
CIN2→ CIN1 (regress) 0.1 per year (probability)
CIN2→ CIN3 0.60 per year (probability)
CIN3→ CIN2 (regress) 0.02 per year (probability)
CIN3→ cervical cancer 0.37 per year (probability)
HPV 6/11→ genital warts 0.30 per year (probability)
Risk of infection
−for HPV 6/11/16 per intercourse 0.3 Elbasha et al. [17]
−for HPV 18 per intercourse 0.13 Modified compared to the HPV 16 risk to
take into account a lower HPV 18 prevalence
Vaccine efficacy 100%
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group of 12-year-olds are followed 61 years etc.).
The vaccine’s possible protection against non-vaccine
HPV types (i.e. cross protection) was not included in the
analyses even though slight evidence suggests that some
cross protection might exist (SPC Gardasil and Cervarix,
http://www.ema.europa.eu/ema). In some studies cross
protection are included (e.g. [29]). Thus, cross protec-
tion in this analysis implies that equal cross protective
efficacy for the two existing vaccines were assumed.
Compared to the previous publication [15], the model
has been adjusted with updated data on cancer incidence
and mortality.
Cost and effects
For each scenario the incremental cost (vaccination cost
minus future costs averted by vaccination) per life year
gained (LYG) and the incremental cost per quality ad-
justed life year (QALY) gained by the HPV-vaccination
was estimated. Given the age distribution for cancer
deaths and that for the general population, it was possibleto estimate the life-years gained (LYG) due to a lower inci-
dence of cervical cancer, anogenital cancer and head and
neck cancer. Similarly, given the modelled decrease in the
specific diseases and given the QALY-weights for the gen-
eral population and the specific diseases (Table 2), the gain
in QALYs was estimated.
A health care sector perspective was applied and in-
cluded direct costs of vaccination and future averted
health care sector costs of HPV-associated diseases. The
applied health care costs appear from Table 3.
Future costs and effects were discounted at a rate of
3% in the base case.
Sensitivity analyses
One-way sensitivity analyses varying one parameter,
while holding other parameters at their base case value,
were performed. The parameters varied appear from
Table 4. Vaccination rate refer to the 3-dose coverage of
12-year-old girls (and boys if applicable).
Based on a recently published study, Danish author-
ities have changed the quadrivalent vaccine regime from
Table 2 QALY weights applied
QALY weights the general population1
Men Women QALY
Age group QALY QALY Occurrence/illness Utility score2 Duration
15-19 0.9373 0.9203
20-24 0.9373 0.9203 CIN1 0.93 2 months
25-29 0.9373 0.9203
30-34 0.9355 0.9118 CIN2-3 0.87 2 months
35-39 0.9197 0.8898
40-44 0.9118 0.8763 Genital warts 0.91 85 days
45-49 0.9050 0.8751
50-54 0.8813 0.8499 Cervical cancer, fatal 0.76-0, 67
55-59 0.8870 0.8542 Cervical cancer, survivors 0.76 5 years
60-64 0.8747 0.8552
65-69 0.8801 0.8098 Genital cancer, fatal 0.76-0.67
70-74 0.8437 0.8320 Genital cancer, survivors 0.76 5 years
75-79 0.8429 0.7837
80-84 0.7855 0.6919 Head & neck cancer, fatal 0.76-0.67
85- 0.7855 0.6919 Head & neck cancer, survivors 0.76 5 years
1Unpublished data from survey performed by National Institute of Public Health, University of Southern Denmark (personal communication). These data, pooled
with two other Danish surveys, are published on a more aggregate level in Sørensen et al., 2009 [31].
2Source: [18].
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with a 2-dose regime was also perfomed (cf. Table 4).
Furthermore, in order to handle the parameter uncer-
tainty multi-way sensitivity analysis was performed.
10,000 model simulations were conducted and in each
simulation the following parameters were randomly
assigned to their base case value or an increased/de-
creased value: vaccination rate (70% or 85%), vaccine
price (market price or market price reduced with 25%),
treatment cost (base case value or reduced with 25%),
discount rate (3% or 5%) and time horizon (62 years
and 40 years). The results of the multi-way sensitivity
analysis were reported as cost-effectiveness acceptabil-
ity curves (Figure 1).
It should be noted that this multi-way sensitivity analysis
did not address all sources of uncertainty as someTable 3 Cost estimates
Cost estimate (PV
Vaccination cost 417 €
Treatment costs – genital warts 247 €
Treatment/control CIN1 and atypia 34 €
Treatment costs CIN2-3 2,780 €
Treatment costs cervical cancer 25,546 €
Treatment costs genital cancer 24,640 €
Treatment costs head & neck cancer 30,400 €
2008 price level. PV: present value. Applied discount rate: 3%.parameters were not included (e.g. duration of relation-
ship, frequency of sexual intercourse). However, these pa-
rameters were varied in the NetLogo simulations as
distribution for these parameters were assumed (cf.
Table 1).
Results
Simulations before the introduction of vaccination showed
that the estimated HPV prevalence replicated the Danish
HPV prevalence (data not shown) fairly precise, indicating
that the model was well calibrated (cf. [15]). When vaccin-
ation was introduced, the prevalence of HPV 6, 11, 16 and
18 decreased and the rate of decrease among others de-
pends on the applied time horizon. Given a 62-year time
horizon, the incidence of e.g. cervical cancer is re-
duced with 74-77% depending on the vaccination) Source
Cost estimates in [15] updated to 2008 price level
Weighted average based on [24]
Weighted average based on [25]
Table 4 Results: Cost-effectiveness of HPV-vaccination in Denmark including protection against genital cancer and head & neck cancer
Average incremental
vaccination costs
per year (€, PV)
Average savings in
treatment costs
per year (€, PV)
Average incremental
cost per year (€, PV)
Average
LYG (PV)
Average QALYs
gained (PV)
ICER
(€/LYG)
ICER
(€/QALY)
Average number
of cases avoided
per year
Vaccinations of girls vs. screening alone:
Base case result* 11,504,613 9,480,325 2,024,288 528.5 565.3 3,830 3,581
Cervical cancer 197
Anogenital cancer 80
Head and neck cancer 43
Univariate sensitivity analysis:
Discount rate 0% 11,504,613 19,622,317 - 8,117,704 1,706.5 1,645.5 Dominance Dominance
Discount rate 5% 11,504,613 6,603,582 4,901,031 265.3 312.5 18,476 15,682
Costs discounted with 3% and LYG & QALYs with 0% 11,504,613 9,480,325 2,024,288 1,706.5 1,645.5 1,186 1,230
Vaccine price reduced by 25% 8,967,267 9,480,325 −513,058 528.5 565.3 Dominance Dominance
2-dose regime 8,121,485 9,480,325 −1,358,840 528.5 565.3 Dominance Dominance
Treatment cost reduced by 25% 11,504,613 7,055,464 4,449,149 528.5 565.3 8,418 7,870
Time horizon 40 years 11,504,613 8,450,127 3,054,486 425.2 472.2 7,184 6,469
Bivalent HPV vaccination (HPV types 16 & 18) 11,504,613 5,269,690 6,234,923 528.5 505.1 11,797 12,345
Protection against head and neck cancer excluded: 11,504,613 9,159,308 2,345,305 432.1 470.4 5,428 4,985
70% vaccination rate 9,474,387 9,320,914 153,473 489.2 551.9 314 278
Cervical cancer 192
Anogenital cancer 77
Head and neck cancer 42
Vaccination of girls & boys vs. girls:
Base case result** 11,858,601 1,186,760 10,671,841 263 256 40,615 41,636
Cervical cancer 5
Anogenital cancer 34
Head and neck cancer 98
Univariate sensitivity analysis:
Discount rate 0% 11,858,601 4,298,652 7,559,950 889 863 8,500 8,763
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Table 4 Results: Cost-effectiveness of HPV-vaccination in Denmark including protection against genital cancer and head & neck cancer (Continued)
Discount rate 5% 11,858,601 587,457 11,271,144 124 122 90,704 92,015
Vaccine price reduced by 25% 9,243,183 1,186,760 8,056,423 263 256 30,661 31,432
2-dose regime 8,371,377 1,186,760 7,184,617 263 256 27,343 28,031
Time horizon 40 years 11,858,601 1,194,383 10,664,218 239 225 44,674 47,342
Protection against head and neck cancer excluded 1,858,601 459,212 11,399,389 42 41 269,857 276,642
70% vaccination rate 9,765,907 1,281,863 8,484,044 301 268 28,146 31,615
2008 price level.
*Vaccination over 62 years (implying that the incremental costs and effects are calculated as an average over the 62 years, assuming vaccination from the first year and onward) of 12-year-old girls compared to screen-
ing alone, 85% vaccination rate, discount rate 3%, 100% vaccine efficacy, vaccine price: € 123 per dose ex. VAT (=market price, source www.promedicin.dk, 10th of May, 2012).
**Vaccination over 62 years of 12-year-old girls and boys compared to 12-year-old girls alone, 85% vaccination rate, discount rate 3%, 100% vaccine efficacy, vaccine price: € 123 per dose ex. VAT (=market price, source
www.promedicin.dk, 10th of May, 2012).
PV: present value; QALY: quality-adjusted life-year; ICER: incremental cost-effectiveness ratio; LYG: life-year gained.
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Figure 1 Cost-effectiveness acceptability curves: proportion of simulations that would be cost-effective given different thresholds
values of cost per QALY gained. It should be noted that this multi-way sensitivity analysis did not address all sources of uncertainty as some
parameters were not included.
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leads to an estimated reduction in the incidence of
cervical cancer on 59%.
In the base case result with a 85% vaccination rate the
cost per QALY gained by female vaccination (compared to
no vaccination) was € 3,581 when including all HPV-
related diseases in the analysis (Table 4). A 85% vaccination
rate is the relavant base case as recently updated Danish
HPV vaccination rate report coverages on 81-90% for 3
doses [33]. Compared to this the cost per QALY gained
when only protection against cervical cancer and pre-
cancerous lesion are included in the analysis is € 20,644
(result not shown in Table 4).
From Table 4 it is seen that the incremental cost-
effectiveness ratios (ICERs) increases with increasing
discount rate, reduced treatment cost, reduced time
horizon and exclusion of protection against head and
neck cancer whereas the ICERs decreases with reduced
discount rate, reduced vaccination rate, reduced vac-
cine price and application of a 2-dose regime. Sensitiv-
ity analysis on reduced vaccine price is relevant as the
vaccine may be offered at a lower price to the health
authorities in a public financed programme. Given a
85% vaccination rate and a 25% reduction in the vac-
cine price or application of a 2-dose regime the average
annual savings in treatment costs outweigh the average
incremental vaccination costs per year, making the vac-
cination program dominant.
Inclusion of the vaccine’s protection against anogenital
cancer and head and neck cancer, (the latter being moreprevalent in men), in the analysis may better address the
relevance of routine vaccination of boys. ICERs of vac-
cination of girls and boys compared to vaccinaition of
girls only appear from Table 4. Compared to vaccination
of girls alone the ICERs are higher and again the ICERs
increases with increasing discount rate, time horizon
and exclusion of protection against head and neck can-
cer while the ICERs decreases with reduced discount
rate, reduced price, application of a 2-dose regime and
reduced vaccination rate.
In Denmark, routine vaccination of girls has been con-
ducted since 2008. Currently some countries have ex-
panded the HPV immunization programme to include
routine vaccination of boys [34]. Therefore, modelling of
universal vaccination of boys and girls compared to vac-
cination of girls alone may be relevant in a Danish
setting. The ICERs are higher implying that it may be
beneficial to include boys in the vaccination program as
well but the additional effect is decreasing as boys to a
certain degree already are protected in a female vaccin-
ation program due to herd protection. On the other
hand, given a cost-effectiveness threshold on 50,000 €
per QALY gained vaccination of boys and girls is esti-
mated to be cost-effective. Vaccinating boys, to prevent
diseases that affect women only (cervical, vulvar, and va-
ginal cancer), lead to relative high ICERs but when all
HPV-related diseases are included (penile cancer, anal
cancer and head and neck cancer) the ICERs for vaccin-
ation of boys and girls versus vaccination of girls alone
dropped markedly.
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analysis is summarized in the cost-effectiveness accept-
ability curves (Figure 1). In Denmark, there is no defined
threshold values of cost per QALY gained but it is seen
from Figure 1 that vaccinating girls is cost-effective even
at relative low thresholds values.
Discussion
This study was based on a Danish agent based model on
HPV transmission and vaccination. The model was ini-
tially developed for the Danish National Board of Health
[27]. This study modelled all HPV related diseases in
males and females as opposed to previous studies focus-
sing primarily on prevention of HPV related cervical
cancers including precursors for cervical cancers.
Denmark has a relatively high incidence of HPV related
diseases in men and women and potential routine vac-
cination of girls and boys has continuously been dis-
cussed after the publication of a Danish Health
Technology Assessment in 2007 [27]. In addition, sev-
eral countries recommend HPV vaccination of boys as
part of the national immunization programme like US,
Australia and Canada and some regions in Germany and
Austria. In Australia for instance, HPV vaccination of all
girls and boys is implemented through a routine school
based programme.
In the base case result (i.e. vaccination of girls only,
85% vaccination rate) an ICER of 3,581 €/QALY is esti-
mated when all HPV-related diseases are taken into ac-
count. Compared to some studies these are relative low
ICERs. However, the results vary with the assumptions
and the results are sensitive to the choice of discount
rate, the choice of time horizon, vaccine price and vac-
cination rate. Seen in that perspective, the range of re-
sults should be considered. However, these Danish
results estimating relative low ICERs is to some extent
due to the high Danish incidence and mortality of HPV
related cancers (e.g. the incidence and mortality from
cervical cancer are among the highest in Europe, cf.
Figure 3.3 and 3.4, page 33 in National Board of Health
[27]). The incidence of genital warts is also relatively
high in Denmark compared with other European coun-
tries [35] - resulting in a relatively large savings potential
when a quadrivalent HPV vaccination program is intro-
duced (the total treatment cost for genital warts is
estimated to 8 mill. € per year [15]).
Comparison with results from others studies analysing
HPV-vaccination in other countries is not straightfor-
ward because of differences in modelling approach (e.g.,
dynamic/agent-based versus cohort models) and other
parameters, including vaccination scenario (2 or 3 doses)
and other country specific conditions. However, the re-
sults for female vaccination only lie within the same
range/level as the study from Elbasha et al. [18] – withthe reservation that Elbasha et al. in principle include a
catch-up programme (in the 2010-publication [15] it is
shown that at catch-up programme increase the ICERs
markedly). When including all HPV-related diseases in an
US-setting Elabasha et al. estimate a mean ICER of 3232 $
per QALY gained in a scenario where girls and women 9-
26 years of age were offered the vaccine [18]. Similarly,
Chesson et al. in an US-setting estimated and ICER of
10500 $ per QALY gained given a 75% vaccination rate
and vaccination of females aged 12-26 years [22].
On the other hand, Kim et al. [19], also in an US-setting,
estimate an ICER of 18,130-20,990 $ per QALY gained in a
scenario where 12-year old girls are vaccinated . The re-
sults are very sensitive to price.
Naturally, this analysis has a number of limitations.
Firstly, only heterosexual transmission of HPV was sim-
ulated ignoring transmission between homosexual and
heterosexual persons. Men who have sex with men
(MSM) have a higher HPV disease burden (genital warts
and anal cancers) and the current HPV programme will
not protect this high-risk ground.
Secondly, unlike most other studies this model did
not include naturally-acquired immunity to HPV in
the simulations.
Thirdly, the model simulates a closed society with no
continuous influx of unvaccinated persons. Increased
globalisation increases the risk of HPV transmission
across national borders thereby lowering the impact of
potential the herd protection of men.
Fourth, 100% vaccine efficacy and lifelong protection
was assumed. Assuming a reduced vaccine efficacy
(99.8% or 93.5%) only change the results on the margin
as shown in the 2010-publication [15]. On the other
hand, inclusion of one booster dose (i.e. assuming that
lifelong protection is not achievable) leads to an increase
in the estimated ICERs (results not shown).
Fifth, it was assumed that the current Danish cervical
screening program remained unchanged. Presently, the
cervical screening program is being reviewed and it may
in the long run be modified due to a decrease in the in-
cidence of cervical cancer. Inclusion of a future modifi-
cation of the screening program, leading to a possible
reduction in the screening cost, in principle should be
taken into account. However, it has not been taken into
account leading to a marginal inaccurate estimation of
future costs related to HPV-vaccination. Although sensi-
tivity and scenario analyses are performed, health
economic analyses using modelling is a simplified repre-
sentation of real life involving several assumptions.
Sixth, two different sources were used for the applied
QALY weights for the general population and for the spe-
cific occurrences/illnesses (Table 2). Furthermore, the
QALY weights for the general population were distributed
according to age group. This can lead to discrepancies. It
Olsen and Jørgensen Cost Effectiveness and Resource Allocation  (2015) 13:4 Page 9 of 10appears from Table 2, for example, that the utility score for
CIN1 was higher than any of the utility scores for the gen-
eral female population, suggesting that the occurrence of
CIN1 will not lead to any QALY loss. This is a limitation
of the analysis, primarily caused by the use of two different
sources for QALY weights. It is thus possible that the total
gain in QALYs is underestimated in the present results.
Finally, possible future variations in the incidence of
HPV-related cancers are not incorporated in the model
simulations. The overall incidence of HPV related can-
cers has increased over the last 30 years in Denmark and
the incidence of head and neck cancers is expected to
increase further in the future. An underestimation of the
future incidence leads to an underestimation of the cost
of head and neck cancer.
Extension of the current HPV programme in Denmark
to include boys and girls is a cost effective preventive
intervention that would lead to a faster prevention of
cancers, cancer precursors and genital warts in Denmark
which is the country in the world with the highest risk
of getting a cancer diagnosis [4].
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